
Agilent Technologies, Inc.

A (Agilent Technologies, Inc.) trades at 0.0x EV/Revenue — attractively valued for a healthcare & pharma company with strong gross margins (52%) and mature growth profile. The business is profitable at 26% EBIT margins.
Cybersecurity spending is growing 15%+ annually as AI both creates and defends against new attack vectors. $280B market by 2028.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Unfortunately, with the ticker "A — A" and limited available information, I cannot provide a reliable assessment of this company's business model, operations, or financial profile. This appears to be either an incomplete ticker symbol, a private company, or potentially outdated/delisted entity in the healthcare sector.
Without access to revenue data, earnings history, or business segment information, it's impossible to assess the company's growth trajectory or quantify market opportunity. Healthcare sector growth typically ranges 3-7% annually, but company-specific performance cannot be determined.
No margin analysis can be conducted without financial statements. Healthcare companies typically show wide profitability variations depending on subsector—biotech often operates at losses while pursuing R&D, whereas established pharma and medical device companies generally maintain healthy margins.
Cannot assess market positioning, competitive advantages, or differentiation strategies without proper company identification and industry context within the broad healthcare sector.
No recent earnings data, stock performance metrics, or quarterly updates are available to evaluate current business momentum or market sentiment shifts.
Analyst coverage, price targets, and consensus estimates cannot be determined without proper company identification and access to research platforms.
This investment opportunity cannot be properly evaluated due to insufficient company information—investors should seek complete financial data and proper company identification before considering any position.
Pre-generated investor questions answered by Claude Opus. Available in the Atlas AI tab.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | — | $7.4B | $7.8B | $8.4B |
| Growth | — | +6% | +6% | |
| EBITDA | — | $2.0B | $2.1B | $2.3B |
| Growth | — | +6% | +6% | |
| EPS (PF) | — | $5.97 | $6.56 | $7.27 |
| Growth | — |
Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026
Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks Transcript
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
Agilent to acquire Biocare Medical in $950 million all-cash deal
Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies
| +10% |
| +11% |